Home » Market News » DirectorsTalk Highlights » Rebooting the immune system with stem cell transplants trialed for Crohn’s disease
WideCells Group PLC

Rebooting the immune system with stem cell transplants trialed for Crohn’s disease

A large trial has been launched in the UK exploring the use of stem cells for treating patients with Crohn’s disease. The radical treatment involves essentially “rebooting” a patient’s immune system and has been used successfully in the past for multiple sclerosis and some cancers.

Crohn’s disease is a chronic inflammatory bowel disease with no clearly understood cause. In severe cases it results in devastating and debilitating symptoms, and rates of diagnoses are increasing in Western countries. A variety of treatments are available to battle the disease, but they often do not work consistently and can have problematic side effects.

Widecells Group (LON:WDC) are leading a transformation in cord blood banking and stem cell treatment; making cord blood banking more accessible through insurance coverage, and increasing the availability of cord blood for transplants.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.